FDA accepts to review Ironwood’s NDA for gout drug Duzallo
Duzallo, which is a fixed-dose combination of lesinurad and allopurinol, is intended to treat hyperuricemia in patients with uncontrolled gout. The drug is likely to be commercially launched in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.